VanEck Biotech ETF (BBH)

NASDAQ: BBH · IEX Real-Time Price · USD
167.74
+1.72 (1.04%)
Jan 31, 2023, 4:00 PM EST - Market closed
1.04%
Assets $531.74M
Expense Ratio 0.35%
PE Ratio 12.66
Shares Out 3.17M
Dividend (ttm) $0.75
Dividend Yield 0.45%
Ex-Dividend Date Dec 19, 2022
Payout Ratio 6.26%
1-Year Return +0.55%
Volume 4,507
Open 167.10
Previous Close 166.02
Day's Range 166.22 - 167.75
52-Week Low 131.12
52-Week High 170.25
Beta 0.85
Holdings 26
Inception Date Dec 20, 2011

About BBH

The VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is managed by VanEck.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol BBH
Issuer Website VanEck
Index Tracked MVIS US Listed Biotech 25

Top 10 Holdings

61.14% of assets
Name Symbol Weight
Amgen Inc. AMGN 11.23%
Gilead Sciences, Inc. GILD 8.18%
Vertex Pharmaceuticals Incorporated VRTX 7.32%
Moderna, Inc. MRNA 5.66%
IQVIA Holdings Inc. IQV 5.39%
Regeneron Pharmaceuticals, Inc. REGN 5.14%
Biogen Inc. BIIB 4.84%
BeiGene, Ltd. BGNE 4.62%
Illumina, Inc. ILMN 4.48%
ICON PLC ICLR 4.27%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 19, 2022 $0.7488 Dec 23, 2022
Dec 20, 2021 $0.3972 Dec 27, 2021
Dec 21, 2020 $0.6079 Dec 28, 2020
Dec 23, 2019 $0.4724 Dec 30, 2019
Dec 20, 2018 $0.551 Dec 27, 2018
Dec 18, 2017 $0.683 Dec 22, 2017
Full Dividend History

News

Brown Brothers Harriman Private Banking Team Expands in Philadelphia

PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...

1 week ago - Business Wire

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

1 week ago - Zacks Investment Research

VanEck Announces Yearend Distributions for VanEck Equity ETFs

NEW YORK--(BUSINESS WIRE)--VanEck announced today the following 2022 annual distributions per share for its VanEck® equity exchange-traded funds.

1 month ago - Business Wire

Biotech Finally Getting Its Groove Back

There's still plenty of room to run to return to prior highs, but some biotech stocks and exchange traded funds are showing signs of life. That's encouraging after what has been a surprisingly long do...

2 months ago - ETF Trends

How Are Biotech ETFs Reacting to Q3 Earnings Releases?

Biotech earnings have come in upbeat in the third quarter.

Other symbols: IBBXBI
2 months ago - Zacks Investment Research

Assessing the Strength of Biotech Dividends With BBH

Biotechnology usually isn't the first industry investors think of when it comes to dividends, but some of the more mature companies in the space do deliver payouts. Some of those names reside in the V...

3 months ago - ETF Trends

Consolidation Case for Biotech ETF BBH

Eight months into 2022, it's fair to say that it's been a tepid year of deal-making in the biotechnology industry, and that's one reason why the related stocks and exchange traded funds are scuffling.

5 months ago - ETF Trends

How Are Biotech ETFs Reacting to Q2 Earnings Releases?

he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

Other symbols: AMGNBIIBGILDIBBXBI
5 months ago - Zacks Investment Research

Biotech Bounce-Back Could Be Durable

Following a lengthy wait that included plenty of downside and frustration, biotechnology stocks and exchange traded funds are finding a groove. For example, the VanEck Vectors Biotech ETF (BBH) is hig...

5 months ago - ETF Trends

3 Best Funds for Aggressive Investors

The best funds for aggressive investors is our topic for today. An aggressive investing strategy typically seeks returns that are greater than those offered by the broader stock market, such as the S&...

Other symbols: BUGRYT
6 months ago - InvestorPlace

Biotech Rebound Could Finally Be Afoot

A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022.

6 months ago - ETF Trends

Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs

Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in i...

Other symbols: GERMIBBQMRNA
6 months ago - ETF Trends

Bank on BBH for Surprising Protection

Owing to its reputation as a growth-heavy industry that's been disappointing investors since early 2021, biotechnology probably isn't the first destination investors think of when seeking shelter-from...

6 months ago - ETF Trends

Biotech Stocks, ETFs Could Be Due for Second Half Rallies

Biotechnology stocks and the related exchange traded funds are in a prolonged slump, and along the way, calls for rebounds have been plentiful. They've also proven inaccurate.

7 months ago - ETF Trends

Basic Could Be Beautiful When Biotech Bounces Back

Biotechnology stocks and exchange traded funds are into a second year of disappointing investors, but that condition won't be permanent. With that in mind, investors evaluating ideas for a biotech res...

8 months ago - ETF Trends

Size Up SBIO as Biotech Catalysts Emerge

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...

Other symbols: BBCIBBSBIO
8 months ago - ETF Trends

Betting on Biotech Bear Market Expiration Date

Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...

Other symbols: BBCIBBSBIO
8 months ago - ETF Trends

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Other symbols: AMGNBIIBGILDIBBXBI
9 months ago - Zacks Investment Research

Positioning for Biotech Bounceback

Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...

Other symbols: BBCIBBSBIO
10 months ago - ETF Trends

Biotech Stocks, ETFs Starting to Look Healthier

Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...

Other symbols: BBCIBBSBIO
11 months ago - ETF Trends

Vaccine Stocks Lift Biotech ETFs as China Enters Lockdowns

Biotechnology sector-related exchange traded funds gained on Monday, with Moderna Inc. (NasdaqGS: MRN) sitting among the top performers in the S&P 500, on renewed COVID-19 concerns as China implements...

11 months ago - ETF Trends

SBIO Is a Good Place to Be for Biotech Innovation

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...

Other symbols: BBCIBBSBIO
1 year ago - ETF Trends

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Other symbols: IBBXBI
1 year ago - Zacks Investment Research

Biotech ETFs Muddled Despite Amgen Strength

Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share b...

Other symbols: IBBIBBQ
1 year ago - ETF Trends

Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit

Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.

Other symbols: IHEUSOXLB
1 year ago - Zacks Investment Research